TWI846843B - 適用於治療高血糖症的雜環基(苯基)甲醇化合物 - Google Patents
適用於治療高血糖症的雜環基(苯基)甲醇化合物 Download PDFInfo
- Publication number
- TWI846843B TWI846843B TW109109482A TW109109482A TWI846843B TW I846843 B TWI846843 B TW I846843B TW 109109482 A TW109109482 A TW 109109482A TW 109109482 A TW109109482 A TW 109109482A TW I846843 B TWI846843 B TW I846843B
- Authority
- TW
- Taiwan
- Prior art keywords
- methanol
- dimethylpyrrolidin
- compound
- group
- chlorophenyl
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/54—Spiro-condensed
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
- C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pyrrole Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1903827.2 | 2019-03-20 | ||
| GBGB1903827.2A GB201903827D0 (en) | 2019-03-20 | 2019-03-20 | New compounds and methods |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| TW202102473A TW202102473A (zh) | 2021-01-16 |
| TWI846843B true TWI846843B (zh) | 2024-07-01 |
Family
ID=66381053
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW109109482A TWI846843B (zh) | 2019-03-20 | 2020-03-20 | 適用於治療高血糖症的雜環基(苯基)甲醇化合物 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20220152004A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3941468A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2022525795A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20210141622A (cg-RX-API-DMAC7.html) |
| CN (1) | CN113784953A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2020243426A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112021018578A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3133768A1 (cg-RX-API-DMAC7.html) |
| GB (1) | GB201903827D0 (cg-RX-API-DMAC7.html) |
| IL (1) | IL286432A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2021011286A (cg-RX-API-DMAC7.html) |
| TW (1) | TWI846843B (cg-RX-API-DMAC7.html) |
| WO (1) | WO2020188301A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201714736D0 (en) | 2017-09-13 | 2017-10-25 | Atrogi Ab | New compounds and uses |
| GB201714745D0 (en) | 2017-09-13 | 2017-10-25 | Atrogi Ab | New compounds and uses |
| GB201714734D0 (en) | 2017-09-13 | 2017-10-25 | Atrogi Ab | New compounds and uses |
| GB201714740D0 (en) | 2017-09-13 | 2017-10-25 | Atrogi Ab | New compounds and uses |
| GB201903832D0 (en) | 2019-03-20 | 2019-05-01 | Atrogi Ab | New compounds and methods |
| GB202204085D0 (en) * | 2022-03-23 | 2022-05-04 | Atrogi Ab | New compounds and methods |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3985887A (en) * | 1973-10-19 | 1976-10-12 | Smithkline Corporation | 3-Substituted-4-hydroxyphenyl-2-piperidylcarbinols as β-adrenergic stimulants |
| WO1999065308A1 (en) * | 1998-06-18 | 1999-12-23 | Novartis Ag | Composition for keeping away vermin |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3910933A (en) * | 1973-10-19 | 1975-10-07 | Smithkline Corp | 3-Substituted-4-hydroxyphenyl-2-piperidylcarbinols |
| ZA756740B (en) * | 1974-10-30 | 1976-10-27 | Scherico Ltd | Azacyclic compounds |
| FR2436779A1 (fr) * | 1978-09-22 | 1980-04-18 | Pharmindustrie | Derives de pyrrolidine-2 methanol utilisables comme medicaments |
| FR2460929A1 (fr) * | 1979-07-06 | 1981-01-30 | Roussel Uclaf | Nouveaux derives de l'a-phenyl 2-pyrrolidinemethanol et leur sels, procede de preparation, application a titre de medicaments et compositions les renfermant |
| EP0128120A3 (de) * | 1983-06-02 | 1985-11-13 | Ciba-Geigy Ag | Trisubstituierte Oxazolidinone |
| JP2002518301A (ja) * | 1998-06-18 | 2002-06-25 | ノバルテイス・アクチエンゲゼルシヤフト | 寄生虫を寄せ付けないための組成物 |
| EP1786410A2 (en) * | 2004-09-07 | 2007-05-23 | Sosei R&D Ltd. | The treatment of inflammatory disorders and pain |
| GB0419828D0 (en) * | 2004-09-07 | 2004-10-13 | Arakis Ltd | The treatment of inflammatroy disorders and pain |
| GB2435979A (en) * | 2006-03-07 | 2007-09-12 | Helen Theresa Haywood | Door intercom telephone device |
| FR2917735B1 (fr) * | 2007-06-21 | 2009-09-04 | Sanofi Aventis Sa | Nouveaux indazoles substitutes, leur preparation et leur utilisation en therapeutique |
| GB201714740D0 (en) * | 2017-09-13 | 2017-10-25 | Atrogi Ab | New compounds and uses |
-
2019
- 2019-03-20 GB GBGB1903827.2A patent/GB201903827D0/en not_active Ceased
-
2020
- 2020-03-20 EP EP20728536.2A patent/EP3941468A1/en active Pending
- 2020-03-20 BR BR112021018578A patent/BR112021018578A2/pt not_active Application Discontinuation
- 2020-03-20 TW TW109109482A patent/TWI846843B/zh active
- 2020-03-20 CN CN202080032751.5A patent/CN113784953A/zh active Pending
- 2020-03-20 AU AU2020243426A patent/AU2020243426A1/en not_active Abandoned
- 2020-03-20 KR KR1020217033753A patent/KR20210141622A/ko not_active Ceased
- 2020-03-20 MX MX2021011286A patent/MX2021011286A/es unknown
- 2020-03-20 JP JP2021556591A patent/JP2022525795A/ja active Pending
- 2020-03-20 WO PCT/GB2020/050762 patent/WO2020188301A1/en not_active Ceased
- 2020-03-20 CA CA3133768A patent/CA3133768A1/en active Pending
- 2020-03-20 US US17/439,668 patent/US20220152004A1/en active Pending
-
2021
- 2021-09-14 IL IL286432A patent/IL286432A/en unknown
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3985887A (en) * | 1973-10-19 | 1976-10-12 | Smithkline Corporation | 3-Substituted-4-hydroxyphenyl-2-piperidylcarbinols as β-adrenergic stimulants |
| WO1999065308A1 (en) * | 1998-06-18 | 1999-12-23 | Novartis Ag | Composition for keeping away vermin |
Non-Patent Citations (1)
| Title |
|---|
| 期刊 Ferre P, et al. "Hypoglycemic effects of a β-agonist, Ro 16-8714, in streptozotocin-diabetic rats: devreased hepatic glucose production and increased glucose utilization in oxidative muscles" Metabolism 41(2): 1992 180-183 * |
Also Published As
| Publication number | Publication date |
|---|---|
| US20220152004A1 (en) | 2022-05-19 |
| BR112021018578A2 (pt) | 2021-11-23 |
| GB201903827D0 (en) | 2019-05-01 |
| MX2021011286A (es) | 2022-01-24 |
| CN113784953A (zh) | 2021-12-10 |
| CA3133768A1 (en) | 2020-09-24 |
| EP3941468A1 (en) | 2022-01-26 |
| AU2020243426A1 (en) | 2021-11-04 |
| JP2022525795A (ja) | 2022-05-19 |
| IL286432A (en) | 2021-10-31 |
| KR20210141622A (ko) | 2021-11-23 |
| WO2020188301A1 (en) | 2020-09-24 |
| TW202102473A (zh) | 2021-01-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2902073T3 (es) | Beta-hidroxietilaminas sustituidas con heteroarilo para uso en el tratamiento de hiperglucemia | |
| JP7346388B2 (ja) | ベータ-ヒドロキシ複素環アミンおよび高血糖症の治療におけるそれらの使用 | |
| KR102849497B1 (ko) | 플루오로페닐 베타-히드록시에틸아민 및 과혈당증의 치료에서의 이의 용도 | |
| TW202102473A (zh) | 適用於治療高血糖症的雜環基(苯基)甲醇化合物 | |
| TWI851687B (zh) | 適用於治療高血糖症的雜芳基(雜環基)甲醇化合物 | |
| US11793774B2 (en) | Chiral beta-hydroxyethylamines and their use in the treatment of hyperglycemia | |
| TW202220956A (zh) | 新穎芳基氮雜雙環[2.1.1]己基甲醇及其醫藥用途 | |
| TW202328071A (zh) | 環己基β-羥基烷基胺類及其醫藥用途 | |
| TW202438055A (zh) | 用於處置高血糖及高血糖為特徵的疾患之取代羥甲基吡咯啶類 | |
| TW202346299A (zh) | 羥甲基氮雜雙環[2.2.1]庚烷及其醫藥用途 | |
| HK40033371B (en) | Heteroaryl substituted beta-hydroxyethylamines for use in treating hyperglycaemia | |
| HK40033371A (en) | Heteroaryl substituted beta-hydroxyethylamines for use in treating hyperglycaemia |